Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

zentiva, k.s., czech republic - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

norameda uab, lithuania - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva b.v., netherlands - teriflunomīds - apvalkotā tablete - 14 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.